Linsitinib (OSI-906)

For research use only. Not for use in humans.

目录号：S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Linsitinib (OSI-906)发表文献91篇：

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)		 Insulin Receptor [1]
(Cell-free assay)		 IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活，IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体，具有良好的代谢稳定性。OSI-906浓度为1μM时，完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖，包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系，EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\UN49pUUN3ME2wMlAzQDB4IN88US=> M3myU3NCVkeHUh?=
KS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nBeGlEPTB;MD6wN|g{PSEQvF2= NWDRcGJkW0GQR1XS
TE-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\SdIw1UUN3ME2wMlA4QDJ{IN88US=> NFrNTZNUSU6JRWK=
EW-1 NXvKS5ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vuWmlEPTB;MD6wPFU5PSEQvF2= NXjpSHE{W0GQR1XS
HMV-II MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj2TWM2OD1yLkC4PFQ3KM7:TR?= M4iz[nNCVkeHUh?=
COLO-205 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLJZ3R6UUN3ME2wMlExPDV2IN88US=> M1vGUnNCVkeHUh?=
ES1 M4j5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP0O29KSzVyPUCuNVA3QTZizszN MnnnV2FPT0WU
GDM-1 NF72OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\2eWlEPTB;MD6xN|Y4OiEQvF2= M2XlSHNCVkeHUh?=
ML-2 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHZV25KSzVyPUCuNVU5QTZizszN NY\1To11W0GQR1XS
Saos-2 MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnwVXNKSzVyPUCuNVY2OjZizszN NHjMSmRUSU6JRWK=
NCI-H1355 M3XDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUixN|Uh|ryP Mk\BV2FPT0WU
G-401 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv5TWM2OD1yLkG4NlMh|ryP MmfHV2FPT0WU
EW-16 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TEcWlEPTB;MD6xPFc4PyEQvF2= NYnHV5BDW0GQR1XS
EW-7 M4\xfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMUi4PFEh|ryP MoTYV2FPT0WU
NCI-H727 M2jmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHTTWM2OD1yLkG5O|k1KM7:TR?= M{LUVnNCVkeHUh?=
LCLC-97TM1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XoeWlEPTB;MD6yNFk2PSEQvF2= NHiyNmJUSU6JRWK=
NCI-H650 NGH2N2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fMcWlEPTB;MD6yNVM5PCEQvF2= MYjTRW5ITVJ?
NCI-H2122 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3KWFNzUUN3ME2wMlI{Ojl7IN88US=> NHrZOm5USU6JRWK=
SK-N-DZ MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;OSmFCUUN3ME2wMlI{Pjl6IN88US=> MV\TRW5ITVJ?
HT-29 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMkSyOFgh|ryP NVzHeFE3W0GQR1XS
LB771-HNC NE\xc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\iV3BKSzVyPUCuNlU6OTVizszN MofqV2FPT0WU
HT-144 M2jl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rtNWlEPTB;MD6yOlE6OSEQvF2= M{nreHNCVkeHUh?=
LAN-6 NY\re3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[4SGtKSzVyPUCuNlY{PDhizszN M{HRfnNCVkeHUh?=
EW-18 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33mUWlEPTB;MD6yO|AxOSEQvF2= MoTWV2FPT0WU
LS-1034 NXXZWmxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjCOplKSzVyPUCuNlcyOzJizszN M1TyfXNCVkeHUh?=
EW-11 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDoboFlUUN3ME2wMlI5PDN{IN88US=> M1vkOnNCVkeHUh?=
SNU-C1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMkmzNVMh|ryP M{m0enNCVkeHUh?=
RS4-11 NXrYS|FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\QZZlKSzVyPUCuN|M4PThizszN NEP5[5FUSU6JRWK=
ES4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GxbmlEPTB;MD60NVA{QCEQvF2= M4XhcXNCVkeHUh?=
COLO-320-HSR MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnaXpRrUUN3ME2wMlQyOzZ6IN88US=> M1TQO3NCVkeHUh?=
NB10 NXLFbJhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrjOZVTUUN3ME2wMlQ2PDN5IN88US=> M2HNNXNCVkeHUh?=
BFTC-905 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor3TWM2OD1yLkS2O|U5KM7:TR?= NXPyc2hpW0GQR1XS
A375 NHvBNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnXTWM2OD1yLkS3OlE4KM7:TR?= NVfkWopnW0GQR1XS
SJRH30 NWL1PXdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNUC4NlIh|ryP Mm\TV2FPT0WU
NOS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln4TWM2OD1yLkWyNlY4KM7:TR?= MnTIV2FPT0WU
SIG-M5 NVrrTIVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHVTWM2OD1yLkWzOVU4KM7:TR?= M3\nS3NCVkeHUh?=
DOK NFnPV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1iyUWlEPTB;MD61OVYh|ryP M1\HU3NCVkeHUh?=
NB69 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnwVJJIUUN3ME2wMlU5OjV5IN88US=> MoCyV2FPT0WU
SK-NEP-1 NUKzUIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rmO2lEPTB;MD62NFI{PiEQvF2= MkL6V2FPT0WU
SK-MM-2 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\VWJlKSzVyPUCuOlU1QTFizszN NV\BVYdpW0GQR1XS
NCI-H358 NHztWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jLemlEPTB;MD62O|A5OiEQvF2= NXXhSo1VW0GQR1XS
RH-1 NH3USFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzIUW9iUUN3ME2wMlc1QDV7IN88US=> M1zSPHNCVkeHUh?=
NH-12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy2WZVqUUN3ME2wMlc3ODR4IN88US=> M4TFc3NCVkeHUh?=
TE-12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwN{[0PFYh|ryP Mk\IV2FPT0WU
COLO-668 M4DKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP3V2J1UUN3ME2wMlg1PjZ4IN88US=> NUntRZdtW0GQR1XS
PANC-08-13 NFfs[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHpTWM2OD1yLki2N|c4KM7:TR?= MYTTRW5ITVJ?
HCC2998 NH7tZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwOEiyOlMh|ryP NHfnPJlUSU6JRWK=
ABC-1 NUSwTFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVeyb|RzUUN3ME2wMlkxOzV{IN88US=> MUfTRW5ITVJ?
ES6 NFzIU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLSTZVLUUN3ME2wMlkyODZ4IN88US=> MXnTRW5ITVJ?
SNU-387 M3jSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfCZVREUUN3ME2wMlk6Ozl|IN88US=> NWL0XYdlW0GQR1XS
CMK M3e2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3tdIVKSzVyPUCuPVk6OjlizszN NFfSWJZUSU6JRWK=
SJSA-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L6VWlEPTB;MT6wN|Y2OyEQvF2= M2jTUXNCVkeHUh?=
SIMA MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPaZ5U6UUN3ME2xMlA3QDJ3IN88US=> MnrpV2FPT0WU
ES3 NHe0fYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwMUKyPVch|ryP NW\VVpN4W0GQR1XS
IGROV-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrkWWNLUUN3ME2xMlE2PDR2IN88US=> M4DCZ3NCVkeHUh?=
MEL-JUSO NXPDbFdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLBVG55UUN3ME2xMlE2PzV7IN88US=> NV3xd2IzW0GQR1XS
T84 M4TrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMkC5NVQh|ryP M17tVnNCVkeHUh?=
CAL-85-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP4TWM2OD1zLkKzNVM5KM7:TR?= NWrFcJlnW0GQR1XS
RD M3TkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T0O2lEPTB;MT6yOlQ2PSEQvF2= NILsS4lUSU6JRWK=
TE-8 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfOXWxyUUN3ME2xMlMyPDZ{IN88US=> NIjZTGtUSU6JRWK=
L-363 M1:xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfXOYFKSzVyPUGuN|QzODhizszN MknCV2FPT0WU
EKVX M4D6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLDfpBKSzVyPUGuN|Q2PjhizszN MkDLV2FPT0WU
SK-MEL-3 NXnz[VRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwNEi1OVYh|ryP M4XqUHNCVkeHUh?=
TGBC24TKB NVrvN45uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwNUCxPVMh|ryP NYTjco5KW0GQR1XS
NCI-H1770 Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP3TWM2OD1zLkWxNVE{KM7:TR?= MmXEV2FPT0WU
HuH-7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPXWGsyUUN3ME2xMlYxODl6IN88US=> NGO4SndUSU6JRWK=
HL-60 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwNk[5Nlgh|ryP MluxV2FPT0WU
TE-1 M1XmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH4OmtFUUN3ME2xMlcxQTR3IN88US=> NUH5[|B1W0GQR1XS
LC-2-ad NV:0VXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwN{O4PFch|ryP NFraPY9USU6JRWK=
LB647-SCLC NUfTRlNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwN{[1PFMh|ryP NXrkT2diW0GQR1XS
NCI-H2171 NGT1O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvDTWM2OD1zLke3O|E3KM7:TR?= NGf4NIZUSU6JRWK=
SK-PN-DW NGGwVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHZZY83UUN3ME2xMlkyOjl6IN88US=> NXPHVVk{W0GQR1XS
MC-IXC MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK4TWM2OD1zLkm4PVgh|ryP NFe0TYxUSU6JRWK=
LS-513 NXvLNXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJwMEWzNFUh|ryP MUjTRW5ITVJ?
EW-3 NUTPdlI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwMEm4OFQh|ryP NFjtOlBUSU6JRWK=
OPM-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwMUCyJO69VQ>? Mlz5V2FPT0WU
LP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJwMkW4NFch|ryP NX;WcZNqW0GQR1XS
LU-134-A NFXTN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2zPY1iUUN3ME2yMlI4PyEQvF2= NIG1SmFUSU6JRWK=
CP66-MEL Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwMkmwNVQh|ryP M{jlN3NCVkeHUh?=
HCC1143 M2XqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PwUGlEPTB;Mj60OVM3QCEQvF2= Ml30V2FPT0WU
LOXIMVI NXXjeIprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD1{Lk[wNlEh|ryP NEfocopUSU6JRWK=
TE-10 NV22dWM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJwN{C4N|gh|ryP MkKwV2FPT0WU
NCI-H1882 NEjvOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\2TWM2OD1{Lke1NlI4KM7:TR?= MXnTRW5ITVJ?
CHP-126 NFv3cmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfoWHloUUN3ME2yMlc3OzF5IN88US=> NFm1SJRUSU6JRWK=
NCI-H1623 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXTTWM2OD1{LkmyNFI1KM7:TR?= M2GzVnNCVkeHUh?=
GB-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLSTI9RUUN3ME2yMlk{PDB2IN88US=> MVnTRW5ITVJ?
RCC10RGB NGfISm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJwOUWyPFEh|ryP MVXTRW5ITVJ?
NCI-H2141 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwOU[4PVYh|ryP NVPjc3BsW0GQR1XS
GI-ME-N M2DCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLKTWM2OD1|LkCwOVY2KM7:TR?= MkfHV2FPT0WU
NCI-H526 Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzhepo6UUN3ME2zMlA1ODh3IN88US=> MUDTRW5ITVJ?
NCI-H747 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[yVpRIUUN3ME2zMlA1QTl{IN88US=> NWLX[IZCW0GQR1XS
SNU-423 M2LEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDIXYVKSzVyPUOuNlA{OTNizszN NHPDUGJUSU6JRWK=
A427 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jIZmlEPTB;Mz6yOVY6QSEQvF2= M1THdXNCVkeHUh?=
CAL-12T NGrGZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXaTWM2OD1|LkSwO|E{KM7:TR?= NWjlSZNkW0GQR1XS
LU-99A MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7DTWM2OD1|LkS3NVA2KM7:TR?= MmLqV2FPT0WU
MS-1 M2i0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXvVlBNUUN3ME2zMlU{PDJ7IN88US=> M1vWUnNCVkeHUh?=
SK-LU-1 NIHrNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwN{[yPVUh|ryP Ml3kV2FPT0WU
SW837 NUTFdFd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPwTWM2OD1|Lke2N|M{KM7:TR?= MWTTRW5ITVJ?
ES8 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNwOEO4O|ch|ryP MlvBV2FPT0WU
MZ2-MEL MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwOUKwPFYh|ryP M2H3WHNCVkeHUh?=
TGW NXzEe2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTRwMEGzNVEh|ryP M4G2dHNCVkeHUh?=
GP5d NIS2N|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT3TWM2OD12LkC1N|YzKM7:TR?= NG\4ZYRUSU6JRWK=
BB49-HNC MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRwMUWyNVMh|ryP MXvTRW5ITVJ?
NB13 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjiO41KSzVyPUSuNlY5QDdizszN NWi2eJJ1W0GQR1XS
NTERA-S-cl-D1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme0TWM2OD12LkK4OlE2KM7:TR?= Mlq4V2FPT0WU
NCI-H1648 M{LIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PrRWlEPTB;ND6yPVgyQSEQvF2= M2CyVnNCVkeHUh?=
LCLC-103H NX\xWFFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f1XGlEPTB;ND6zNlE6PSEQvF2= NF7zZnlUSU6JRWK=
LS-411N MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTRwNES4PFUh|ryP Mmf5V2FPT0WU
NCI-H1092 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnQeHBPUUN3ME20MlQ2Pjh5IN88US=> MofjV2FPT0WU
PANC-10-05 NWTzZXpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorwTWM2OD12Lk[5PFQh|ryP NH;5UVlUSU6JRWK=
DK-MG NYDNfo4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33XfWlEPTB;ND64NFk{OyEQvF2= MlvkV2FPT0WU
OVCAR-5 NWTTZYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXNTWM2OD12LkixNlI3KM7:TR?= NGC2VGxUSU6JRWK=
CAL-39 MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojsTWM2OD12Lki3Olch|ryP MXPTRW5ITVJ?
TE-441-T NYrJbZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwOUC1N|ch|ryP NYjy[25GW0GQR1XS
MOLT-16 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxXJBKSzVyPUSuPVUzPTNizszN MUXTRW5ITVJ?
MCF7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorQTWM2OD13LkG0OVE4KM7:TR?= MXfTRW5ITVJ?
CAPAN-1 NGO3NmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvafZpwUUN3ME21MlI2PzB5IN88US=> M4L6[XNCVkeHUh?=
PSN1 M2CxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTVwMkeyN|Uh|ryP NFH0XGVUSU6JRWK=
NCI-H292 NEm1bm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTjS3ZKSzVyPUWuN|AxPDRizszN MYHTRW5ITVJ?
CPC-N MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TOTGlEPTB;NT6zPVQyQSEQvF2= Mn3lV2FPT0WU
DoTc2-4510 MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\JTWM2OD13LkS1N|cyKM7:TR?= M1;aTHNCVkeHUh?=
LB1047-RCC MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLMTWM2OD13LkW1PVM{KM7:TR?= MW\TRW5ITVJ?
MHH-ES-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\WRlRKSzVyPUWuOVk6ODdizszN MknlV2FPT0WU
NMC-G1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTVwN{CyNlch|ryP MlvkV2FPT0WU
SW1710 NV[yOoc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\oeFdKSzVyPUWuO|Q4PTFizszN NYG2TWJQW0GQR1XS
YAPC M2LBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrMdHZOUUN3ME21Mlc3OjBzIN88US=> M2\ReHNCVkeHUh?=
22RV1 NFrHUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnNTWM2OD13LkiwNFE6KM7:TR?= NGjIfYhUSU6JRWK=
COLO-679 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDibYJKSzVyPUWuPFg6PDhizszN NHzpVHVUSU6JRWK=
TCCSUP MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzwRnFKSzVyPUWuPVMzPTlizszN NF3FWYJUSU6JRWK=
C2BBe1 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHYXW1KSzVyPUWuPVM6PyEQvF2= NYCyR|M6W0GQR1XS
TE-15 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm5Z|dKSzVyPU[uNFY3ODVizszN MojLV2FPT0WU
SCLC-21H MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjmTWM2OD14LkGwPFQ{KM7:TR?= M3n4O3NCVkeHUh?=
EoL-1-cell M2i5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXncHNyUUN3ME22MlE3PTZ|IN88US=> NVXRU2FkW0GQR1XS
NKM-1 NXnZXmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTZwMU[3NUDPxE1? M1HGWHNCVkeHUh?=
NCI-H1304 M2XMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTZwMke0Nlgh|ryP M1:ycHNCVkeHUh?=
NB6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ewfmlEPTB;Nj6yPVYzOiEQvF2= NH\HNpdUSU6JRWK=
NALM-6 Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTPTWM2OD14LkOzNlMh|ryP MnH3V2FPT0WU
NCI-H522 NULZbo1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LWXmlEPTB;Nj6zN|MxPiEQvF2= MV;TRW5ITVJ?
MV-4-11 NEniO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTZwM{ewO|kh|ryP MkPNV2FPT0WU
LB2241-RCC M{TPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr3XWFKSzVyPU[uN|g3PjdizszN NGjrNWhUSU6JRWK=
NCI-H1417 M4rKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\rTWM2OD14LkSwPFQ4KM7:TR?= MnraV2FPT0WU
HT-1197 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZwNUexNlIh|ryP M1TlfHNCVkeHUh?=
P30-OHK M3q3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTZwNkK3O{DPxE1? NV\veY5iW0GQR1XS
ALL-PO Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTZwN{G5NVYh|ryP NHLSOXlUSU6JRWK=
OVCAR-4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTGcI1KSzVyPU[uO|U1ODVizszN MUTTRW5ITVJ?
HCC2157 M1nGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7weVBEUUN3ME22Mlc4PDd3IN88US=> M2riT3NCVkeHUh?=
NCI-H838 NF\KU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTZph7UUN3ME22Mlk3PDlizszN MUDTRW5ITVJ?
NCI-H1299 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwOUewPUDPxE1? M1zVZnNCVkeHUh?=
SW954 M1jVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTdwMkCwOlgh|ryP Ml21V2FPT0WU
NCI-H441 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTdwM{SwOlUh|ryP NVjwUVBYW0GQR1XS
SK-MEL-2 NXj4S2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTdwNEizO|Mh|ryP M{DEeXNCVkeHUh?=
KARPAS-45 NG\Od5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTOeGxRUUN3ME23MlY2QTJ7IN88US=> M1v3fnNCVkeHUh?=
CAL-54 NH\C[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7nTXYyUUN3ME23MlgzQTd5IN88US=> MVXTRW5ITVJ?
KYSE-180 NHLjemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPJWmZKSzVyPUeuPFg6PDFizszN MUXTRW5ITVJ?
NCI-H187 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LZOmlEPTB;Nz65OVk1PyEQvF2= M{HyfnNCVkeHUh?=
RT-112 NWHaO2w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjT[WpnUUN3ME24MlA6Pjd5IN88US=> NXjpb3VYW0GQR1XS
NCI-H1437 NEDT[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[1O3VKSzVyPUiuNFk4QTVizszN MlyzV2FPT0WU
SNU-449 NV;2T3V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzHUnhtUUN3ME24MlI5Ojd{IN88US=> M3\ifXNCVkeHUh?=
HCC1187 NGOxeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1TWM2OD16LkK5N|kyKM7:TR?= MXPTRW5ITVJ?
NCI-H2030 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV62[5B7UUN3ME24MlM4PzF2IN88US=> MoLHV2FPT0WU
HuO-3N1 NVTicFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnpcYxCUUN3ME24MlM4QDR2IN88US=> NFPmW21USU6JRWK=
COLO-792 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRThwNEG1Nlch|ryP M3TaW3NCVkeHUh?=
MIA-PaCa-2 NHzxdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSz[otKSzVyPUiuPFU2ODhizszN MYHTRW5ITVJ?
SK-N-FI MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTlwMESyOUDPxE1? MUjTRW5ITVJ?
MMAC-SF M4juXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqwVJJKSzVyPUmuNFk4PTFizszN MUjTRW5ITVJ?
NCI-H28 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4frN2lEPTB;OT6xNFQ3QSEQvF2= MmDyV2FPT0WU
ETK-1 NHzvSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTlwMkm5O|Qh|ryP Moi1V2FPT0WU
NCI-H1993 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGniXoFKSzVyPUmuOFQzPjFizszN Mm\1V2FPT0WU
no-11 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTlwNEexNkDPxE1? MVzTRW5ITVJ?
ChaGo-K-1 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLpTWM2OD17LkWxOVg{KM7:TR?= NUjZb|hoW0GQR1XS
NCCIT MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7GV4pKSzVyPUmuOVMyPjlizszN MmrCV2FPT0WU
SAS MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fLSGlEPTB;MUCuNlQ5KM7:TR?= MXrTRW5ITVJ?
A673 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFyLkO3NFQh|ryP MmXnV2FPT0WU
NCI-H1522 M1L0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFyLkO3NFch|ryP MXLTRW5ITVJ?
NCI-H810 NWHDUFhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjO[mlKSzVyPUGwMlM6ODdizszN NGK0V4dUSU6JRWK=
IST-MES1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrVTWM2OD1zMD60OVY1KM7:TR?= MnzRV2FPT0WU
GR-ST NGfaOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvMTWM2OD1zMD61NFI1KM7:TR?= NYH4e29QW0GQR1XS
SUP-T1 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFmxZnBKSzVyPUGwMlc{OTdizszN NVvneJM4W0GQR1XS
NB5 NWTOOWU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK1U|NNUUN3ME2xNE46ODJ{IN88US=> Mnu4V2FPT0WU
MZ1-PC NXPueJF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fub2lEPTB;MUCuPVU4OSEQvF2= MULTRW5ITVJ?
SK-CO-1 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFyLkm5N|Eh|ryP NUnUbnNMW0GQR1XS
Capan-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnLS5FKSzVyPUGxMlMyQThizszN MnPSV2FPT0WU
697 NFX1cmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XLc2lEPTB;MUGuOlc2PyEQvF2= NEHpUY9USU6JRWK=
REH NFjBcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPpTpY6UUN3ME2xNU44PDVzIN88US=> NIm4NXRUSU6JRWK=
GI-1 NELER|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHXb|JPUUN3ME2xNU45PjF3IN88US=> NGrH[mRUSU6JRWK=
BB65-RCC MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHrTWM2OD1zMj6wPVE3KM7:TR?= M4\XO3NCVkeHUh?=
NCI-H1651 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXmd2RmUUN3ME2xNk4zPDd6IN88US=> MmWxV2FPT0WU
NCI-H1618 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[wT3NOUUN3ME2xNk4{QTd4IN88US=> Mn\DV2FPT0WU
NCI-H2081 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jR[mlEPTB;MUKuOlE1OSEQvF2= MmfrV2FPT0WU
GCIY NY\vW3NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q3U2lEPTB;MUKuO|IyOyEQvF2= NX;hV3ZPW0GQR1XS
NY M3HXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjzTWM2OD1zMz6wOlQ{KM7:TR?= NXH4cZh1W0GQR1XS
PANC-03-27 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;tTGlEPTB;MUOuNFgxPyEQvF2= MVXTRW5ITVJ?
BHY NYTiXXhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF|LkKxNlEh|ryP NX7TWHV2W0GQR1XS
SK-OV-3 M331Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKxOVhyUUN3ME2xN{4{PzZ|IN88US=> M2DYXnNCVkeHUh?=
5637 NWDKPGI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn0Tm13UUN3ME2xN{44PzV7IN88US=> MWDTRW5ITVJ?
LC-1F MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPlO5RKSzVyPUG0MlA{PTZizszN NYLYeFI1W0GQR1XS
SNB75 NUHEdVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF20bm5KSzVyPUG0MlA{QDNizszN NWqyfXVxW0GQR1XS
CHP-212 M2HYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHhd2xKSzVyPUG0MlA1PjRizszN NV7kdlc1W0GQR1XS
HT-1376 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\KdW1xUUN3ME2xOE4yOTJ4IN88US=> M{nRNHNCVkeHUh?=
MONO-MAC-6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;RTWM2OD1zND6xOVAzKM7:TR?= NGfRVmhUSU6JRWK=
CA46 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17vOWlEPTB;MUSuNVgzPyEQvF2= Mm\wV2FPT0WU
SCC-15 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f5ZmlEPTB;MUSuOVU5OyEQvF2= NWjQXoJxW0GQR1XS
ATN-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuxXGtRUUN3ME2xOE43PjJ5IN88US=> MnLUV2FPT0WU
NCI-H2405 M1fFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDpVVFKSzVyPUG0MlgyPTdizszN NVLx[|JWW0GQR1XS
NCI-H716 M{HU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCUmlEPTB;MUSuPFQ6OyEQvF2= M2S2[HNCVkeHUh?=
SW620 NFX3VWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3jUppKSzVyPUG0MlkxOTRizszN NFvpVZRUSU6JRWK=
NCI-H226 NEPqWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF2LkmwPFUh|ryP NXzCbYtYW0GQR1XS
SW962 NIXj[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf0UWFHUUN3ME2xOE46PDN{IN88US=> M4noWXNCVkeHUh?=
KYSE-150 M{TmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\EPXdXUUN3ME2xOE46PTVizszN M1TWdXNCVkeHUh?=
OCUB-M MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\C[o1KSzVyPUG0Mlk5QDNizszN M1n4RnNCVkeHUh?=
ES7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF3LkC5PFQh|ryP NXfWdGVrW0GQR1XS
SW1463 M3fyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLPSI1KSzVyPUG1MlQzOjNizszN MoryV2FPT0WU
CAKI-1 NGXEcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljrTWM2OD1zNT61N|Q3KM7:TR?= NHLXT4FUSU6JRWK=
MKN28 NVPGfWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\UcmlEPTB;MUWuOVQ4QSEQvF2= MXLTRW5ITVJ?
SW13 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni1TWM2OD1zNT62NVgh|ryP NXnjdoxXW0GQR1XS
A3-KAW M2Plcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzH[mxKSzVyPUG1Mlk3QTdizszN MWnTRW5ITVJ?
LU-65 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LV[WlEPTB;MUWuPVc3QCEQvF2= NVjOXndkW0GQR1XS
Calu-1 NXHueYJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLwSIxKSzVyPUG2MlA{PjhizszN MVHTRW5ITVJ?
ST486 NWXmN4FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF4LkC0N|Eh|ryP NYr0SGdXW0GQR1XS
BB30-HNC M4HqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK5S2hXUUN3ME2xOk4yOjR4IN88US=> NHy2OJVUSU6JRWK=
EGI-1 NVTFRo5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTkTWM2OD1zNj60OFYh|ryP MX\TRW5ITVJ?
SH-4 MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LsR2lEPTB;MU[uOFc{OSEQvF2= NYW2eGZnW0GQR1XS
MN-60 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fzT2lEPTB;MUeuNlI6PyEQvF2= MVvTRW5ITVJ?
MPP-89 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XMNGlEPTB;MUeuNlQ2QSEQvF2= NUfpTJRjW0GQR1XS
A2780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjtVm01UUN3ME2xO{41OTN7IN88US=> NYDSPYV4W0GQR1XS
Daoy MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzIcpgyUUN3ME2xO{41Pjl3IN88US=> M{fkd3NCVkeHUh?=
NCI-H2126 NXX3SI1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjMTJdKSzVyPUG3MlQ4PzFizszN MYfTRW5ITVJ?
NCI-H1563 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL4Xo5SUUN3ME2xO{41QTF5IN88US=> NHHMSlRUSU6JRWK=
8-MG-BA NHXwdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PhbGlEPTB;MUeuOlY1QCEQvF2= M{LzcXNCVkeHUh?=
786-0 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O4VGlEPTB;MUeuPFM2OyEQvF2= NWjYTFRUW0GQR1XS
AM-38 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\qbpZmUUN3ME2xO{46OzB4IN88US=> M1;aUXNCVkeHUh?=
COLO-824 M4\KeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLvTWM2OD1zOD60OFM3KM7:TR?= M{Xa[nNCVkeHUh?=
SK-MEL-30 M1LEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF6LkWwPFIh|ryP NI\pUXJUSU6JRWK=
CESS NXT1RWxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF6Lke2NFkh|ryP NGP4RnVUSU6JRWK=
BL-70 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojtTWM2OD1zOD64NVU3KM7:TR?= M3fOUXNCVkeHUh?=
NCI-H2170 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHrfZJYUUN3ME2xPE46OTd7IN88US=> NHLHfllUSU6JRWK=
HT-3 NX;hfYRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF6Lkm4N{DPxE1? NXW0dIlFW0GQR1XS
BOKU MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPCVpRHUUN3ME2xPU4xOzhzIN88US=> NXPlXlZpW0GQR1XS
HPAF-II NXHGSmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF7LkOwNVUh|ryP M3T3b3NCVkeHUh?=
KGN NGjFS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF7LkS3OlUh|ryP NHrNNVRUSU6JRWK=
MC-CAR Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF7Lk[zNVMh|ryP MXjTRW5ITVJ?
BHT-101 M1K0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13rSGlEPTB;MUmuO|c4KM7:TR?= NH7CSJVUSU6JRWK=
SW1783 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDDNWpwUUN3ME2xPU44QDB4IN88US=> NVi0[FF[W0GQR1XS
KP-N-YN MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW1b5pNUUN3ME2yNE4xOjZ{IN88US=> MWnTRW5ITVJ?
LU-165 NFTBSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W1e2lEPTB;MkCuOVU4OSEQvF2= M3XDbXNCVkeHUh?=
GOTO MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf2NlJRUUN3ME2yNE43PDVzIN88US=> M4HSOnNCVkeHUh?=
EFM-19 M2rkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITMPJRKSzVyPUKxMlA4OTZizszN NVPBdVhKW0GQR1XS
CTV-1 M1fIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jzR2lEPTB;MkGuNVA2PCEQvF2= MkPnV2FPT0WU
HEL NXe2cFVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXlWVN[UUN3ME2yNU41OjF4IN88US=> NXvOXFRlW0GQR1XS
SNU-C2B MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULkUmR1UUN3ME2yNU41OjZizszN NIL1SW5USU6JRWK=
ECC4 M{PGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[0WZBKSzVyPUKxMlcxPyEQvF2= M2fJSHNCVkeHUh?=
NEC8 M3TORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HHdWlEPTB;MkGuPFM3QCEQvF2= MUnTRW5ITVJ?
KMOE-2 NH63Z2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJzLki5NlEh|ryP NFfnR4hUSU6JRWK=
NCI-H524 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPwTWM2OD1{Mj6wPFA5KM7:TR?= MYfTRW5ITVJ?
WSU-NHL M2fuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJ{LkG1O|ch|ryP Ml\VV2FPT0WU
SF126 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfNTWM2OD1{Mj6yOFY6KM7:TR?= NWXZXJV5W0GQR1XS
HOP-92 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrW[3NKSzVyPUKyMlMyPjdizszN MXTTRW5ITVJ?
CTB-1 NIWwVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XEeWlEPTB;MkKuOFY4PyEQvF2= NFfIW5lUSU6JRWK=
KYSE-270 NX7Od5FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPYNXhKSzVyPUKyMlk{PTdizszN NFrVfXVUSU6JRWK=
SK-MEL-24 M3fnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;LXmxKSzVyPUKzMlE5PyEQvF2= NYPBWll[W0GQR1XS
Calu-3 M{X6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17xbWlEPTB;MkOuNlEzQCEQvF2= M3XTS3NCVkeHUh?=
GAMG MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37UPGlEPTB;MkOuNlM3PyEQvF2= NX7wem5IW0GQR1XS
SW1573 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ|Lke0NVUh|ryP M3;Pb3NCVkeHUh?=
MHH-NB-11 M2XlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPJOJoxUUN3ME2yOE4xOTl2IN88US=> Mn:3V2FPT0WU
TK10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSxTm5ZUUN3ME2yOE42ODF|IN88US=> NVXGOm1iW0GQR1XS
LB373-MEL-D MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljCTWM2OD1{ND62NFY1KM7:TR?= NEC2O2RUSU6JRWK=
KALS-1 M3ezTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDRPYIzUUN3ME2yOE44OzJ5IN88US=> M37ROnNCVkeHUh?=
HUTU-80 MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPjTWM2OD1{NT64NFMzKM7:TR?= M2LmfnNCVkeHUh?=
HuP-T3 NWm4T|JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fPNGlEPTB;Mk[uNVY4PCEQvF2= MkjtV2FPT0WU
OE19 NGrHVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ4LkKxOVMh|ryP MoTCV2FPT0WU
J82 Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrZOXlKSzVyPUK2MlI1PzFizszN NUPqVXE2W0GQR1XS
DU-4475 NWDQcZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ4LkO4NVkh|ryP MWnTRW5ITVJ?
DMS-53 NWLkeJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ4LkWxN|gh|ryP NYD0dHZ1W0GQR1XS
COLO-741 NVnx[JFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnwSnpKSzVyPUK2Mlg{PDRizszN M3joPXNCVkeHUh?=
SW48 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\BTWM2OD1{Nj64PFIh|ryP MYDTRW5ITVJ?
IGR-1 M1mxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ4LkmzN|Qh|ryP NHK2dFdUSU6JRWK=
639-V M4r0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ5LkCyOFUh|ryP Ml3qV2FPT0WU
LK-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M132O2lEPTB;MkeuOFE1OSEQvF2= M1\KSXNCVkeHUh?=
NCI-H2347 NG[yPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrelhTUUN3ME2yO{46Pjl7IN88US=> MnXlV2FPT0WU
NCI-H2228 NISxNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWzTWM2OD1{OD6wPVA2KM7:TR?= NGHCS|RUSU6JRWK=
LS-123 M1PYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfjZWdKSzVyPUK4MlEzPjJizszN MUXTRW5ITVJ?
U031 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLDbJNKSzVyPUK4MlI2OiEQvF2= NVH3WIFyW0GQR1XS
NCI-H1792 NYfRPHdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M334WWlEPTB;MkiuOFczOSEQvF2= MXfTRW5ITVJ?
NCI-H2087 NH63V4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3jTWM2OD1{OD63OVUzKM7:TR?= MUfTRW5ITVJ?
NCI-H2342 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX4bW93UUN3ME2yPU42OjB6IN88US=> MVfTRW5ITVJ?
SW626 M3LiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOyW3dKSzVyPUK5Mlc2PiEQvF2= MnfpV2FPT0WU
LB2518-MEL NGjITVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3UT4pKSzVyPUK5MlgyPSEQvF2= MmnRV2FPT0WU
RXF393 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfCclhwUUN3ME2zNE4xQTV{IN88US=> NHLwfFNUSU6JRWK=
LC4-1 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf3TWM2OD1|MD6zNFkzKM7:TR?= MkjDV2FPT0WU
NCI-H1694 NUXP[2V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyzTWM2OD1|MD62OlI1KM7:TR?= NH;wZppUSU6JRWK=
K5 M3Pi[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LRXmlEPTB;M{CuPVcxOiEQvF2= NIfFS29USU6JRWK=
HDLM-2 M4DWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLESmpUUUN3ME2zNE46PzJ3IN88US=> MUPTRW5ITVJ?
BCPAP M2nh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj5VGpOUUN3ME2zNU45Ozd7IN88US=> MXnTRW5ITVJ?
BC-3 NIHobINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonyTWM2OD1|Mj6xOFA{KM7:TR?= NUTmT5RDW0GQR1XS
LB996-RCC M1TmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXpTWM2OD1|Mj6yN|U5KM7:TR?= M4rWXHNCVkeHUh?=
NCI-H2009 NWf4Zlk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN{LkS5PFEh|ryP NVqxZnE4W0GQR1XS
HTC-C3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nXNmlEPTB;M{OuO|UyQSEQvF2= MkXuV2FPT0WU
LAMA-84 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHkTWM2OD1|ND60OFA4KM7:TR?= MmK4V2FPT0WU
CCRF-CEM NV;jbnc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3mSINKSzVyPUO0MlU4OTVizszN NF7PTINUSU6JRWK=
AN3-CA MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN3LkC1Olgh|ryP NY\6bYFpW0GQR1XS
NCI-H1734 MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q1RWlEPTB;M{WuNlU3OSEQvF2= NYLyZ3R1W0GQR1XS
Ca-Ski MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjyXWFKSzVyPUO1MlQyODFizszN NVHmU|F3W0GQR1XS
U-266 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX61TldSUUN3ME2zOU43OTF2IN88US=> MoO2V2FPT0WU
SBC-5 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrMTWM2OD1|NT63O|gyKM7:TR?= NF73W2dUSU6JRWK=
GT3TKB MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjxd|RKSzVyPUO3MlEyPSEQvF2= M{XmUHNCVkeHUh?=
MDA-MB-175-VII MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Hu[WlEPTB;M{euNlI1QCEQvF2= MlLlV2FPT0WU
PFSK-1 NUW2Nmk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3yelhsUUN3ME2zO{4zPDN3IN88US=> M3LERXNCVkeHUh?=
IMR-5 NYPZV5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrzUWtKSzVyPUO3MlI1QDdizszN NF31eWhUSU6JRWK=
Daudi NIHt[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTN5LkO1PVch|ryP M17aN3NCVkeHUh?=
A498 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\LTWM2OD1|Nz63NlE5KM7:TR?= NUfmdWdxW0GQR1XS
SCC-4 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTN5Lke4OFMh|ryP M3\KN3NCVkeHUh?=
COLO-680N NFTtZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;5blhKSzVyPUO4MlI5QDVizszN MWLTRW5ITVJ?
SK-MES-1 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTN6LkOyNVUh|ryP NEDBd4NUSU6JRWK=
SR MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf2TWM2OD1|OD61OFk2KM7:TR?= MUjTRW5ITVJ?
LNCaP-Clone-FGC NXfFSHVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr0fHBKSzVyPUO4MlU3OzdizszN NHnpcGFUSU6JRWK=
SK-HEP-1 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXywbYJ{UUN3ME2zPE44QDJ{IN88US=> M3PibnNCVkeHUh?=
BPH-1 M3vmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP4c2pQUUN3ME2zPE45OzJ7IN88US=> NY\5RZJTW0GQR1XS
NCI-H1755 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX32b|ZtUUN3ME2zPU42QDF5IN88US=> MmnBV2FPT0WU
LXF-289 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HVW2lEPTB;M{muPFA5PCEQvF2= MljEV2FPT0WU
SW1088 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSyWG9yUUN3ME20NE4zOTB5IN88US=> NG\NbJJUSU6JRWK=
MOLT-4 NHzwTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL0OoxKSzVyPUSwMlI6ODFizszN M1K2VHNCVkeHUh?=
AsPC-1 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG3S4JKSzVyPUSwMlQ2QDNizszN MkixV2FPT0WU
HOP-62 M37xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTRyLk[1Olgh|ryP MXXTRW5ITVJ?
A172 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvaTWM2OD12MD64OVEyKM7:TR?= M4PJWXNCVkeHUh?=
SN12C MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT4U|lKSzVyPUSwMlk{QDVizszN NWjKcYx[W0GQR1XS
MDA-MB-231 M1j5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:4TWM2OD12MD65PFk5KM7:TR?= NWD0VI94W0GQR1XS
RPMI-2650 M{jYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRzLkG1PVMh|ryP NFr1eZlUSU6JRWK=
KYSE-140 MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHkTWM2OD12MT64NVI{KM7:TR?= MXPTRW5ITVJ?
KINGS-1 NEHlc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\IS2lEPTB;NEKuOFY6PyEQvF2= NYTkVJVNW0GQR1XS
HSC-3 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmzZ|hIUUN3ME20Nk43PjZzIN88US=> M{H3eXNCVkeHUh?=
PC-14 NVHZNWVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m1UWlEPTB;NEOuNVg5OiEQvF2= NYP4N|ZPW0GQR1XS
COR-L105 NGn1O5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXMOZNrUUN3ME20N{43PTB{IN88US=> NVOyW4U2W0GQR1XS
BE-13 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuwcGg1UUN3ME20OE4zOzdzIN88US=> M121T3NCVkeHUh?=
NCI-H661 M36w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3QOHcyUUN3ME20OE4zQTV6IN88US=> MnjuV2FPT0WU
IST-MEL1 NXvwUmIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljrTWM2OD12ND6zOVk6KM7:TR?= MnW4V2FPT0WU
HCC1806 M2HxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r3eGlEPTB;NESuOVg4OyEQvF2= NHjCOnNUSU6JRWK=
COLO-800 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTR2Lki0OVMh|ryP M2rvcnNCVkeHUh?=
IST-SL2 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnMUINKSzVyPUS1MlEzPDdizszN M1mwfnNCVkeHUh?=
8305C MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13uPWlEPTB;NEWuN|A6KM7:TR?= MV7TRW5ITVJ?
UACC-62 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[4TWM2OD12Nj6yPFc2KM7:TR?= NIrwPXpUSU6JRWK=
COR-L23 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfGcIF7UUN3ME20O{4yQTlizszN NF7SRpZUSU6JRWK=
EFE-184 M3fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTR5LkO4PEDPxE1? MlHRV2FPT0WU
DMS-114 M3j1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3NO5lKSzVyPUS3MlQyPDlizszN NVv6WmwyW0GQR1XS
KYSE-520 NHrwdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTR6LkWzNVUh|ryP M3LVdXNCVkeHUh?=
SNG-M NYXJNYJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPrWVVMUUN3ME20PU41OzRizszN MoXnV2FPT0WU
A2058 NFu5VJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fq[2lEPTB;NEmuOFg5PSEQvF2= MYfTRW5ITVJ?

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型，抑制肿瘤生长，按 75 mg / kg剂量处理，导致100% TGI和 55% 衰退，按25 mg/kg剂量处理，导致 60% TGI，没有衰退。OSI-906处理犬，大鼠和小鼠，诱导不同的消除半衰期，消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠，每天一次，Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天，提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型，在4 和24小时间最大程度抑制IGF-IR磷酸化(80%)，血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠，处理2，4，24小时，抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型，抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
- 合并

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中，使用聚 (Glu:Tyr)作为底物，结合到96孔实验板表面，使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物，通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中，人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白，且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验，除非另有说明，取三次测量的最小值。
细胞实验：[1]
- 合并
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖，细胞接种在含FCS 10%的合适培养基上，在不同浓度OSI-906存在时，温育3天。通过细胞内ATP含量的荧光量化，使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分，通过在不同浓度 OSI-906存在时的细胞密度除以对照组（只用DMSO处理）细胞密度。
    (Only for Reference)
动物实验：[1]
- 合并
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理，每天一次，持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
 6.25mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O
CAS号 867160-71-2
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答：

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

Selleck产品目录册

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

  • 泛IGF-1R抑制剂

    GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • 活性最高的IGF-1R抑制剂

    BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • 用于临床的IGF-1R抑制剂

    BMS-754807 : Phase II for Breast Cancer.

  • 最新的IGF-1R抑制剂

    PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

相关IGF-1R产品

  • Picropodophyllin (PPP) New

    Picropodophyllin (PPP)是一种选择性IGF-1R抑制剂，IC50为1 nM。它对IGF-IR具有高选择性，对IR的酪氨酸磷酸化或FGF-R、PDGF-R、EGF-R没有抑制作用。Picropodophyllin (PPP)可诱导凋亡并具有抗肿瘤活性。

  • Erlotinib New

    Erlotinib 是一种EGFR抑制剂，IC50 为 2 nM，对EGFR的敏感性比对人c-Src 或 v-Ab高1000多倍。Erlotinib可诱导自噬。

  • Bemcentinib（R428) New

    R428 (BGB324)是一种Axl抑制剂，IC50为14 nM，作用于Axl比作用于Abl选择性高100倍以上。作用于Axl选择性也比作用于Mer和Tyro3(高50到100倍)及InsR， EGFR， HER2，和PDGFRβ(高100倍以上)高。

  • BMS-536924

    BMS-536924是一种ATP竞争性的IGF-1R抑制剂，IC50为100 nM，对Mek， Fak，和Lck也具有适中的抑制活性，但对Akt1，和MAPK1/2几乎无抑制活性。

  • NVP-AEW541

    NVP-AEW541是一种有效的IGF-1R/InsR抑制剂，在无细胞试验中IC50为150 nM/140 nM，在细胞试验中对IGF-1R具有较高的作用和选择性。

  • NVP-ADW742

    NVP-ADW742是一种IGF-1R抑制剂，IC50为0.17 μM，作用于IGF-1R比作用于InsR效果强16倍以上；对HER2， PDGFR， VEGFR-2， Bcr-Abl和c-Kit几乎没有活性。

  • GSK1904529A

    GSK1904529A是一种选择性的IGF-1R和IR抑制剂，无细胞试验中IC50分别为27 nM和25 nM，作用于IGF-1R/InsR比作用于Akt1/2/， Aurora A/B，B-Raf， CDK2， EGFR等选择性高100倍以上。

  • BMS-754807

    BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂，在无细胞试验中IC50为1.8 nM/1.7 nM，对Met，Aurora A/B，TrkA/B和Ron作用稍弱，对Flt3， Lck，MK2，PKA，PKC等几乎没有抑制活性。Phase 2。

    Features:胰岛素样生长因子-1R/IR家族激酶的多重抑制剂

  • AG-1024

    AG-1024 抑制IGF-1R自磷酸化，IC50为7 μM，对IR作用效果稍弱，IC50为57 μM，且特异性区分InsR和IGF-1R（相比于其他酪氨酸磷酸化抑制剂）。

  • PQ 401

    PQ 401抑制IGF-1R区域自磷酸化，IC50为低于1 μM。

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID